BORIS Isoform Detection and Immune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cancer are limited in their ability to identify additional antigens linked to hyperproliferative diseases, such as cancer, and have low positive predictive value for detection and prognosis, necessitating the identification of new markers and methods for diagnosing and treating diseases associated with abnormal BORIS expression.
Innovation Solution
Development of methods and compositions for detecting abnormal BORIS expression in mammals, including testing for BORIS isoforms in tissues or body fluids, using siRNA molecules, anti-BORIS antibodies, and BORIS isoform mRNA transcripts, as well as inducing an immune response by administering BORIS isoforms, with the aid of kits and arrays for BORIS expression detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cancer detection methods are used, then detection can be performed with existing technology, but the ability to identify additional antigens linked to hyperproliferative diseases is limited and positive predictive value is low
Solution Approach 1:
The patent segments the detection approach by identifying and testing for multiple specific BORIS isoforms (such as isoform 1, isoform 2, etc.) rather than using a single general cancer marker. This segmentation allows for more precise identification of cancer types and improves positive predictive value by distinguishing between different cancer conditions through specific isoform patterns.
Solution Approach 2:
The patent changes the detection parameter from general cancer markers to specific BORIS isoform expression patterns. By measuring the presence and levels of different BORIS isoforms in tissue or body fluid samples, the method achieves higher measurement precision and positive predictive value while maintaining the ability to identify multiple antigen types.
2Reliability
If BORIS isoform detection methods are implemented, then detection accuracy and diagnostic value are improved, but the complexity of the detection system increases
Solution Approach 1:
The patent applies universality by developing a multi-functional detection system that can identify multiple BORIS isoforms using a single comprehensive assay approach. The detection method serves multiple purposes: diagnosing cancer, determining cancer type, monitoring treatment response, and prognosticating patient outcomes, thereby reducing the need for multiple separate detection systems.
Solution Approach 2:
The patent uses BORIS isoform expression patterns as an intermediary marker that connects disease state to detectable signals. By measuring isoform levels in accessible body fluids or tissues, the method provides a reliable diagnostic indicator without requiring direct observation of cancer cells, thus improving reliability while managing detection complexity.
3Adaptability or versatility
If multiple BORIS isoforms are tested for detection, then comprehensive cancer identification is achieved, but the time and resources required for analysis increase
Solution Approach 1:
The patent merges the detection of multiple BORIS isoforms into a single integrated testing procedure. Rather than performing separate assays for each isoform, the method combines detection of multiple isoforms (isoform 1, isoform 2, and others) in one comprehensive test, achieving comprehensive cancer identification while minimizing the time and resources required by consolidating the analytical process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective detection and treatment of diseases characterized by abnormal BORIS expression, such as cancer, by identifying specific BORIS isoforms and inducing an immune response, thereby improving diagnostic and therapeutic outcomes.
Implementation Method 1
the siRNA molecule comprises a sequence of at least 10 contiguous nucleotides that is complimentary to a BORIS isoform mRNA transcript
Implementation Method 2
administering an anti-BORIS antibody to a mammal afflicted with a disease associated with abnormal BORIS expression, wherein the anti-BORIS antibody selectively binds to a isoform polypeptide
Data Source
AI summary
A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same.